{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:50:28Z","timestamp":1765039828555},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2836,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2000,10]]},"abstract":"<jats:p><jats:bold>Abstract<\/jats:bold><jats:bold> Background:<\/jats:bold> \u03b1 \u2212Interferons are the accepted therapy for patients infected with chronic hepatitis C virus (HCV) in China. However, consensus interferon (CIFN) for HCV treatment is effective in patients with chronic hepatitis C from Western countries.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This randomized, controlled trial was conducted to determine the safety and efficacy of CIFN at two doses, and to compare it with \u03b1\u20102a\u2010interferon (IFN\u2010\u03b1\u20102a) in Chinese patients with chronic HCV. Interferon\u2010naive patients with chronic HCV infection (<jats:italic>n<\/jats:italic> = 187) were randomly chosen to receive 15 \u03bcg CIFN or 9 \u03bcg or 3 MU IFN\u2010\u03b1\u20102a subcutaneously, three times a week for 24 weeks, followed by a 24 week observation period. Efficacy was evaluated by the normalization of serum alanine aminotransferase (ALT) and the non\u2010detectability disappearance of serum HCV\u2010RNA by using reverse\u2010transcription\u2013polymerase chain reaction. The safety of CIFN was evaluated by recording the type and severity of adverse effects.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The combined ALT and HCV\u2010RNA end\u2010of\u2010treatment and sustained responses were observed to be greater for treatment with 15 \u03bcg CIFN (59.0% and 55.7%, respectively) compared to IFN \u03b1\u20102a (36.1% and 39.3%, respectively; <jats:italic>P<\/jats:italic> = 0.01 for the end\u2010of\u2010treatment, <jats:italic>P<\/jats:italic> = 0.07 for the sustained response). The combined ALT and HCV\u2010RNA end\u2010of\u2010treatment and sustained responses for treatment with 9 \u03bcg CIFN (both 49.2%) were higher than those for IFN\u2010\u03b1\u20102a (not statistically significant). Data were analyzed by using a logistic\u2010multiple\u2010variate regression model, which indicated that the higher IFN dose (15 \u03bcg or 9 \u03bcg CIFN <jats:italic>vs<\/jats:italic> 3 MU IFN\u2010\u03b1\u20102a; <jats:italic>P<\/jats:italic> &lt; 0.01) appeared to be associated with a better sustained response. The type, frequency and severity of adverse effects were comparable across treatment groups.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Consensus interferon appears to be safe and effective at concentrations of 9 and 15 \u03bcg, but 15 \u03bcg CIFN may be more effective than 3 MU IFN\u2010\u03b1\u20102a, without increased toxicity.<\/jats:p>","DOI":"10.1046\/j.1440-1746.2000.02307.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T05:12:55Z","timestamp":1047445975000},"page":"1165-1170","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A multicenter, randomized, controlled trial of interferon alfacon\u20101 compared with <b>\u03b1<\/b>\u20102a\u2010interferon in Chinese patients with chronic hepatitis C virus infection"],"prefix":"10.1111","volume":"15","author":[{"given":"Guang\u2010Bi","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi\u2010Xian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng\u2010Shan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao\u2010Zhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian\u2010Jie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Shan","family":"Huangfu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2010Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"60","article-title":"Viral hepatitis in China: seroepidemiological survey in Chinese population (Part one: 1992\u20135).","volume":"9","author":"Dai ZC","year":"1997","journal-title":"Science & Technology Archives Publications"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260704"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260713"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240405"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1992.12.55"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1996.16.489"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190538"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190629"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260718"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260330"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270431"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260721"},{"key":"e_1_2_5_15_2","first-page":"490","article-title":"Hepatitis C virus infection and genotypes.","volume":"16","author":"Yao DF","year":"1996","journal-title":"J. Nantong Med. School"},{"key":"e_1_2_5_16_2","first-page":"212","article-title":"HCV genotypes distribution in chronic hepatitis C infection patients from Shanghai region.","volume":"5","author":"Jin GD","year":"1997","journal-title":"J. Chinese Hepatol."},{"key":"e_1_2_5_17_2","first-page":"922","article-title":"Long\u2010term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.","volume":"111","author":"Yao GB","year":"1998","journal-title":"Chin. Med. J."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01382.x"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1746.2000.02307.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1746.2000.02307.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T03:22:00Z","timestamp":1697340120000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1746.2000.02307.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["10.1046\/j.1440-1746.2000.02307.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1746.2000.02307.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10]]},"assertion":[{"value":"2008-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}